{"id":783772,"date":"2023-09-13T10:36:16","date_gmt":"2023-09-13T14:36:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/"},"modified":"2023-09-13T10:36:16","modified_gmt":"2023-09-13T14:36:16","slug":"abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/","title":{"rendered":"AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology"},"content":{"rendered":"

<\/p>\n

AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology<\/b><\/p>\n

VANCOUVER, British Columbia–(BUSINESS WIRE<\/a>)–AbCellera<\/a> (Nasdaq:ABCL) announced today that it has entered into a strategic collaboration with Incyte (Nasdaq:INCY) to discover and develop therapeutic antibodies in oncology.<\/p>\n

\n\u201cWe are excited to partner with Incyte, which has a track record of developing first-in-class medicines and bringing them to patients in need,\u201d said Murray McCutcheon, Ph.D., Senior Vice President of Partnering at AbCellera. \u201cWe look forward to working as an extension of Incyte\u2019s team to address complex antibody discovery challenges and accelerate the development of Incyte\u2019s preclinical pipeline of oncology medicines.\u201d<\/p>\n

\n\u201cThis collaboration supports our continued commitment to developing new therapeutics that may improve and expand treatment options for patients with cancer,\u201d said Patrick Mayes, Ph.D., Vice President, BioTherapeutics at Incyte. \u201cWe are excited to partner with AbCellera to initiate this research and look forward to collaborating with them to identify new antibody therapeutics that may address unmet needs in oncology.\u201d<\/p>\n

\nUnder the financial terms of the agreement, Incyte has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive downstream clinical and regulatory milestone payments and royalties on net sales of products.<\/p>\n

About AbCellera Biologics Inc.<\/b><\/p>\n

\nAbCellera is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. AbCellera\u2019s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com<\/a>.<\/p>\n

AbCellera Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management\u2019s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.<\/p>\n

\nIn some cases, you can identify forward-looking statements by the words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230912918216\/en\/<\/a><\/span><\/p>\n

Inquiries
\n
<\/b>Media: Jessica Yingling, Ph.D.; media@abcellera.com<\/a>, +1(236)521-6774
\n
Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com<\/a>, +1(604)559-9005
\n
Investor Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com<\/a>, +1(778)729-9116<\/p>\n

KEYWORDS:<\/b> United States North America Canada<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Technology Other Technology Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera (Nasdaq:ABCL) announced today that it has entered into a strategic collaboration with Incyte (Nasdaq:INCY) to discover and develop therapeutic antibodies in oncology. \u201cWe are excited to partner with Incyte, which has a track record of developing first-in-class medicines and bringing them to patients in need,\u201d said Murray McCutcheon, Ph.D., Senior Vice President of Partnering at AbCellera. \u201cWe look forward to working as an extension of Incyte\u2019s team to address complex antibody discovery challenges and accelerate the development of Incyte\u2019s preclinical pipeline of oncology medicines.\u201d \u201cThis collaboration supports our continued commitment to developing new therapeutics that may improve and expand treatment … <\/p>\n

Continue reading “AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-783772","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera (Nasdaq:ABCL) announced today that it has entered into a strategic collaboration with Incyte (Nasdaq:INCY) to discover and develop therapeutic antibodies in oncology. \u201cWe are excited to partner with Incyte, which has a track record of developing first-in-class medicines and bringing them to patients in need,\u201d said Murray McCutcheon, Ph.D., Senior Vice President of Partnering at AbCellera. \u201cWe look forward to working as an extension of Incyte\u2019s team to address complex antibody discovery challenges and accelerate the development of Incyte\u2019s preclinical pipeline of oncology medicines.\u201d \u201cThis collaboration supports our continued commitment to developing new therapeutics that may improve and expand treatment … Continue reading "AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-13T14:36:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230912918216r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology\",\"datePublished\":\"2023-09-13T14:36:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\\\/\"},\"wordCount\":682,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230912918216r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\\\/\",\"name\":\"AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230912918216r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-09-13T14:36:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230912918216r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230912918216r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/","og_locale":"en_US","og_type":"article","og_title":"AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology - Market Newsdesk","og_description":"AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera (Nasdaq:ABCL) announced today that it has entered into a strategic collaboration with Incyte (Nasdaq:INCY) to discover and develop therapeutic antibodies in oncology. \u201cWe are excited to partner with Incyte, which has a track record of developing first-in-class medicines and bringing them to patients in need,\u201d said Murray McCutcheon, Ph.D., Senior Vice President of Partnering at AbCellera. \u201cWe look forward to working as an extension of Incyte\u2019s team to address complex antibody discovery challenges and accelerate the development of Incyte\u2019s preclinical pipeline of oncology medicines.\u201d \u201cThis collaboration supports our continued commitment to developing new therapeutics that may improve and expand treatment … Continue reading \"AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-13T14:36:16+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230912918216r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology","datePublished":"2023-09-13T14:36:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/"},"wordCount":682,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230912918216r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/","name":"AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230912918216r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-09-13T14:36:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230912918216r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230912918216r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/783772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=783772"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/783772\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=783772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=783772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=783772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}